Mengjun Zhong, Rili Gao, Ruocong Zhao, Youxue Huang, Cunte Chen, Kehan Li, Xibao Yu, Dingrui Nie, Zheng Chen, Xin Liu, Zhuandi Liu, Shaohua Chen, Yuhong Lu, Zhi Yu, Liang Wang, Peng Li, Chengwu Zeng, Yangqiu Li
Sustained expression of programmed cell death receptor-1 (PD-1) is correlated with the exhaustion of T cells, and blockade of the PD-1 pathway is an effective immunotherapeutic strategy for treating various cancers. However, response rates are limited, and many patients do not achieve durable responses. Thus, it is important to seek additional strategies that can improve anticancer immunity. Here, we report that the bromodomain and extraterminal domain (BET) inhibitor JQ1 inhibits PD-1 expression in Jurkat T cells, primary T cells, and T-cell exhaustion models...
August 2, 2022: Cell Death & Disease